Heraldnet.com
SUNDAY, SEPTEMBER 5, 2010 2:15 pm
LocalNorthwestNation & WorldPoliticsSpecial ReportsPhotosColumnistsMultimedia 
Blog
Michelle Dunlop
787 goes to extremes
Blog
Amy Rolph
25 years for Northwest Software Technologies of Everett
Mike Benbow
Business editor Mike Benbow's insights into all things business.
•Latest: A wary take on health care bill
Steve Tytler
Steve Tytler answers your questions about real estate.
•Latest: What to do when surveys conflict
 
WEEK IN REVIEW
Saturday
Team of detectives investigate death of Sultan ...
Man dead after encounter with deputies in Gold Bar
Three people killed in wreck on Whidbey Island
Friday
3 killed in crash on Whidbey Island
Accident closes part of Highway 20
Bail set at $1 million for man in pursuit
Thursday


Man accused of shooting at police had allegedly...
Lynnwood notifies more than 100 employees of po...
New temporary police chief named in Granite Falls
Wednesday


A stroke of kindness for Everett woman
Suspect arrested in Everett manhunt after shots...
New student exams, familiar results
Tuesday


Crash leaves car embedded in Everett Transit bus
County students get mixed grade from superinten...
Stevens Hospital District taxes to stay
Monday


More than a nuisance
Mukilteo's red-light camera fight on radar of ...
Renamed Keystone ferry terminal a coup for Coup...
Sunday


Snohomish County becomes a destination for airp...
You’ll need only 1 flu shot this year
Snohomish County YMCA goal: Healthy kids
 

ADVERTISEMENT

Business   Print This Article  Email This Page  Subscribe Now! facebook digg reddit del.icio.us fark stumble

 
 
CONTACT THE HERALD
Mike Benbow, Business Editor
benbow@heraldnet.com
 
Published: Wednesday, March 21, 2007

MediQuest looks to attract investors

SEATTLE - MediQuest Therapeutics Inc. has two potential treatments in late-stage human tests, an experienced management team and more than $16 million raised from investors last year.

Which made the job of interesting investors in the company a little easier for Fred Dechow, chief executive of the Bothell biotechnology firm.

Dechow was one of dozens of biotech executives trying to make their case to investors Tuesday at the sixth annual Invest Northwest forum. The event, organized by the Washington Biotechnology & Biomedical Association, continues today in downtown Seattle.

While venture capitalists seem to be willing again to place their bets on biotech companies, they're not throwing money at just anyone. They're mostly looking at companies that are beyond the startup phase.

"It's amazing what they call early stage now," said Dechow of MediQuest, which was founded in 1984. "Some investors still consider us early stage because we don't have any revenue from drugs yet."

Bruce Helberg, who works in the Kirkland office of Silicon Valley Bank, said companies that already have attracted some money in the past and that have a "great" team at the helm are more likely to catch the eye of financiers.

Among the 50 or so biotech companies presenting at Invest Northwest, about 10 are located in Bothell or Mukilteo. Many, including Seattle Genetics, Sonus Pharmaceuticals and Nastech Pharmaceutical, already are publicly held companies.

MediQuest isn't there yet. The money it raised last year was its first from true venture capitalists, instead of smaller "angel" investors. It hopes to submit a new drug application to regulators this summer for its treatment for Raynaud's phenomenon, a sometimes painful reaction to cold temperatures in the fingers and toes that affects primarily women.

Dechow said he was happy with his presentation to investors. Whether it wins the company any new investors, only time will tell.

Reporter Eric Fetters: 425-339-3453 or fetters@heraldnet.com.

Other Advertisers
TODAY'S TOP JOBS
 View All Top Jobs 
Top Cars
Top Homes

ADVERTISEMENT